$6995 | Single User
$13990 | Site License
$20985 | Enterprise License

Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023
[Published by Global Data]

Published by Global Data: 01 Nov 2015 | 27219 | In Stock
Related Topics: Multiple Myeloma , Myeloma

Introduction

Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023

Summary

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

The 5EU market is forecast to show a larger increase in size. This is due to the launch of premium priced Kyprolis, Empliciti, and daratumumab, as well as the later launch of Revlimid and Velcade generics, compared to the US.

Scope

- Overview of Multiple Myeloma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in 5EU from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Multiple Myeloma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Myeloma.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table of Contents
for Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 6

    1.2 List of Figures 10

    2 Introduction 11

    2.1 Catalyst 11

    2.2 Related Reports 12

    2.3 Upcoming Related Reports 12

    3 Disease Overview 13

    3.1 Etiology and Pathophysiology 13

    3.1.1 Etiology 13

    3.1.2 Pathophysiology 13

    3.2 Staging Systems 16

    3.3 Response and Relapse Criteria 17

    3.4 Symptoms 19

    3.5 Prognosis 20

    3.6 Quality of Life 21

    4 Disease Management 24

    4.1 Treatment Overview 24

    4.2 Diagnosis 25

    4.3 Clinical Practice 26

    4.3.1 Primary Therapy for SCT-Eligible Patients 27

    4.3.2 Primary Therapy for Non-SCT Patients 29

    4.3.3 Salvage/Relapse Therapy 30

    4.3.4 Leading Prescribed Drugs 31

    4.4 France 34

    4.4.1 Diagnosis 35

    4.4.2 Clinical Practice 36

    4.5 Germany 36

    4.5.1 Diagnosis 38

    4.5.2 Clinical Practice 38

    4.6 Italy 39

    4.6.1 Diagnosis 40

    4.6.2 Clinical Practice 40

    4.7 Spain 42

    4.7.1 Diagnosis 43

    4.7.2 Clinical Practice 43

    4.8 UK 44

    4.8.1 Diagnosis 45

    4.8.2 Clinical Practice 46

    5 Competitive Assessment 47

    5.1 Overview 47

    5.2 Product Profiles - Proteasome Inhibitors 47

    5.2.1 Velcade (Bortezomib) 47

    5.2.2 Kyprolis (Carfilzomib) 54

    5.3 Product Profiles - Immunomodulators 62

    5.3.1 Revlimid (Lenalidomide) 62

    5.3.2 Pomalyst/Imnovid (Pomalidomide) 69

    5.4 Other Therapeutic Classes 74

    6 Unmet Need and Opportunity 75

    6.1 Overview 75

    6.2 Treatment of High-Risk Patients 75

    6.2.1 Unmet Need 75

    6.2.2 Gap Analysis 76

    6.2.3 Opportunity 77

    6.3 Treatment of Patients with Smoldering Myeloma 77

    6.3.1 Unmet Need 77

    6.3.2 Gap Analysis 79

    6.3.3 Opportunity 79

    6.4 Treatment of Extramedullary Disease 80

    6.4.1 Unmet Need 80

    6.4.2 Gap Analysis 80

    6.4.3 Opportunity 81

    7 Pipeline Assessment 82

    7.1 Overview 82

    7.2 Promising Drugs in Clinical Development 82

    7.2.1 Farydak (Panobinostat) 82

    7.2.2 Ixazomib 89

    7.2.3 Empliciti (Elotuzumab) 94

    7.2.4 Daratumumab 100

    7.2.5 Aplidin (Plitidepsin) 105

    7.3 Promising Drugs in Early-Stage Development 109

    7.3.1 Oprozomib (ONX-0912) 109

    7.3.2 Filanesib 110

    7.3.3 SAR650984 110

    7.3.4 Marizomib 112

    7.3.5 Evofosfamide 112

    7.3.6 LGH447 113

    7.3.7 Selinexor (KPT-330) 113

    8 Market Outlook 115

    8.1 5EU 115

    8.1.1 Forecast 115

    8.1.2 Key Events 119

    8.1.3 Drivers - 5EU 119

    8.1.4 Barriers - 5EU 121

    9 Appendix 124

    9.1 Bibliography 124

    9.2 Abbreviations 146

    9.3 Methodology 150

    9.4 Forecasting Methodology 150

    9.4.1 Diagnosed Multiple Myeloma Patients 150

    9.4.2 Percent of Drug-Treated Patients 151

    9.4.3 Drugs Included in Each Therapeutic Class 151

    9.4.4 Launch and Patent Expiry Dates 152

    9.4.5 General Pricing Assumptions 153

    9.4.6 Individual Drug Assumptions 154

    9.4.7 Pricing of Pipeline Agents 161

    9.4.8 Generic Erosion 168

    9.5 Primary Research - KOLs Interviewed for this Report 169

    9.6 Primary Research - High-Prescriber Survey 171

    9.7 About the Authors 172

    9.7.1 Analyst 172

    9.7.2 Therapy Director 172

    9.7.3 Epidemiologist 172

    9.7.4 Global Head of Healthcare 173

    9.8 About GlobalData 174

    9.9 Disclaimer 174

List Of Tables
in Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.1 List of Tables

Table 1: Definition of the Classes of Myeloma 15

Table 2: Staging Systems for Multiple Myeloma 17

Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response 18

Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression 18

Table 5: Symptoms of Multiple Myeloma 19

Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma 20

Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression 21

Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma 21

Table 9: Treatment Guidelines for Multiple Myeloma 25

Table 10: Definition of the Classes of Myeloma 26

Table 11: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014 31

Table 12: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013 32

Table 13: Country Profile - France 34

Table 14: Country Profile - Germany 37

Table 15: Country Profile - Italy 39

Table 31: Country Profile - Spain 42

Table 17: Country Profile - UK 45

Table 18: Product Profile - Velcade 48

Table 19: Results from the Pivotal Phase III APEX Trial for Velcade 50

Table 20: Results from the Pivotal Phase III VISTA Trial for Velcade 51

Table 21 Results from the Subcutaneous versus Intravenous Velcade Phase III trial 51

Table 22: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials 52

Table 23: Velcade SWOT Analysis, 2015 53

Table 24: Global Sales Forecast ($m) for Velcade, 2013-2023 53

Table 25: Product Profile - Kyprolis 55

Table 26 Summary of Phase III Pivotal Trial Results for Kyprolis 58

Table 27: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis 59

Table 28 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis 60

Table 29: Kyprolis SWOT Analysis, 2015 61

Table 30: Global Sales Forecasts ($m) for Kyprolis, 2013-2023 62

Table 31: Product Profile - Revlimid 63

Table 32 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients 65

Table 33 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients 66

Table 34: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid 67

Table 35: Revlimid SWOT Analysis, 2015 68

Table 36: Global Sales Forecast ($m) for Revlimid, 2013-2023 68

Table 37: Product Profile - Pomalyst 69

Table 38: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst 71

Table 39: Summary of Phase III Trial Data for Pomalyst 72

Table 40: Pomalyst SWOT Analysis, 2015 73

Table 41: Global Sales Forecasts ($m) for Pomalyst, 2013-2023 73

Table 42: Summary of Other Therapeutic Classes, 2015 74

Table 43: Pipeline Product Profile - Farydak 83

Table 44: Summary of the Phase III PANORAMA 1 Trial of Farydak 86

Table 45: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Recived at Least Two Prior Lines of Therapy (Including Velcade and an IMiD) 86

Table 46: Summary of the Phase II PANORAMA 2 Trial of Farydak 87

Table 47: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak 87

Table 48: Farydak SWOT Analysis, 2015 89

Table 49: Global Sales Forecast ($m) for Farydak, 2013-2023 89

Table 50: Pipeline Product Profile - Ixazomib 90

Table 51: Response Results from the Phase II Study of Ixazomib 92

Table 52: Ixazomib SWOT Analysis, 2015 93

Table 53: Global Sales Forecast ($m) for Ixazomib, 2013-2023 94

Table 54: Pipeline Product Profile - Empliciti 95

Table 55: Summary of the Phase III ELOQUENT 2 trial of Empliciti 97

Table 56: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone 98

Table 57: Empliciti SWOT Analysis, 2015 99

Table 58: Global Sales Forecast ($m) for Empliciti, 2013-2023 99

Table 59: Pipeline Product Profile - Daratumumab 100

Table 60: Response Results from the Phase II Study of Daratumumab 102

Table 61: Daratumumab SWOT Analysis, 2015 104

Table 62: Global Sales Forecast ($m) for Ddaratumumab, 2013-2023 104

Table 63: Pipeline Product Profile - Aplidin 105

Table 64: Summary of Phase II Clinical Trial Results for Aplidin 107

Table 65: Summary of Grade 3 and 4 Adverse Events of Aplidin 107

Table 66: Aplidin SWOT Analysis, 2015 108

Table 67: Global Sales Forecast ($m) for Aplidin, 2013-2023 108

Table 68: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib 110

Table 69: Summary of the Phase I Efficacy Results of SAR650984 111

Table 70: Summary of the Phase I Efficacy Results of Evofosfamide 113

Table 71: 5EU Sales Forecast, Multiple Myeloma, 2013-2023 ($m) 115

Table 72: Key Events Impacting Sales for Multiple Myeloma in the 5EU, 2013-2023 119

Table 73: 5EU Multiple Myeloma - Drivers and Barriers, 2013-2023 119

Table 74: 5EU Multiple Myeloma - Barriers, 2013-2023 121

Table 75: Multiple Myeloma Diagnosed Incidence, 2013-2023 151

Table 76: Multiple Myeloma Drugs and Pipeline agents, Launch Dates 152

Table 77: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries 153

Table 78: Average Cost of Therapy for Velcade 155

Table 79: Average Duration of Treatment (Weeks) for Velcade 155

Table 80: Average Cost of Therapy for Kyprolis ($) 157

Table 81: Average Duration of Treatment (Weeks) for Kyprolis 157

Table 82: Average Cost of Therapy for Revlimid ($) 158

Table 83: Average Duration of Treatment (Weeks) for Revlimid 159

Table 84: Average Cost of Therapy for Pomalyst/Imnovid ($) 160

Table 85 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid 160

Table 86: Average Cost of Therapy for Farydak ($) 161

Table 87: Duration of Treatment (Weeks) for Farydak 162

Table 88: Average Cost of Therapy for Ixazomib ($) 163

Table 89: Duration of Treatment (Weeks) for Ixazomib 163

Table 90: Average Cost of Therapy for Empliciti ($) 164

Table 91: Duration of Treatment (Weeks) for Empliciti 165

Table 92: Average Cost of Therapy for Daratumumab ($) 166

Table 93: Duration of Treatment (Weeks) for Daratumumab 167

Table 94: Average Cost of Therapy for Daratumumab ($) 168

Table 95: Duration of Treatment (Weeks) for Daratumumab 168

Table 96: Numbers of Prescribers Surveyed in Each Country 171

List Of Figures, Charts and Diagrams
in Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data]

1.2 List of Figures

Figure 1: SCT-Eligible Typical Patient Journey 27

Figure 2: Non-SCT-Eligible Typical Patient Journey 29

Figure 3: Velcade’s Phase III Development in Multiple Myeloma 49

Figure 4: Kyprolis’s Phase III Development in Multiple Myeloma 56

Figure 5: Revlimid’s Phase III Development in Multiple Myeloma 63

Figure 6: Pomalyst/Imnovid’s Phase III Development in Multiple Myeloma 70

Figure 7: Farydak’s Development in Multiple Myeloma 85

Figure 8: Dosing Schedule for Farydak 88

Figure 9: Ixazomib’s Development in Multiple Myeloma 91

Figure 10: Empliciti's Development in Multiple Myeloma 95

Figure 11: Daratumumab’s Development in Multiple Myeloma 102

Figure 12: Annual 5EU Sales for Multiple Myeloma by Region, 2013-2023 116

Figure 13: Annual 5EU Sales for Multiple Myeloma by Drug, 2013-2023 117

Figure 14: 5EU Sales for Multiple Myeloma by Drug, 2013 and 2023 118

Additional Details

Publisher

Global Data

Publisher Information

Reference

27219 | GDHC307CFR

Number of Pages

175

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Global Data

Download Free Report Summary PDF

Multiple Myeloma - 5EU Drug Forecast and Market Analysis to 2023 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...